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Abstract 
Mefloquine hydrochloride has been used widely in the past few decades for malaria prophylaxis and treatment. How-
ever, in recent years, it has fallen out of favor due to reports of exposure being linked to numerous neuropsychiatric 
effects, including emotional disturbances. In this study we examined the effects of different doses (5, 25, or 100 mg/
kg) of mefloquine relative to vehicle on male C57BL/6 J mice in two tests of emotional behavior, the light–dark box 
and the tail suspension test. It was found that mefloquine exposure reduced anxiety-linked behaviors in the light–
dark box and reduced total immobility times in the tail suspension test, especially at higher doses. Our results lend 
support to the notion that mefloquine exposure could induce emotional disinhibition.
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Background
Mefloquine hydrochloride [dl-erythro-α-(-2-piperidyl)-2, 
8-bis (trifluoromethyl)-4-quinolinemethanol], histori-
cally has been used as a prophylactic and treatment agent 
for malaria infection caused by Plasmodium falciparum 
(Nevin 2012a; Magill 2006). Mefloquine was developed at 
the Walter Reed Army Institute of Research in the 1970’s 
and had been marketed under the trade name Lariam, 
among others (Nevin 2012b). Due to its long half-life in 
the body (Yelmo et al. 2010), allowing for weekly rather 
than daily treatment, and its efficacy against chloroquine-
resistant forms of the disease (Nevin 2012b), mefloquine 
was employed widely among travelers to areas where 
malaria infection was likely (Nevin 2012b; Petersen et al. 
2000; van Riemsdijk et  al. 1997, 2005; Phillips and Kass 
1996) including members of the U.S. military deployed 
overseas to such areas as Iraq and Afghanistan (Nevin 
2010; Peterson et al. 2011; Vuurman et al. 1996).
In the past 10–15  years, concerns about mefloquine’s 
neuropsychiatic side effects have grown. Initially it was 
believed that side effects were rare (1 in every 10,000 
cases; Choo 1996). Yet, numerous case studies of travel-
ers with (Wittes and Saginur 1995; Even et al. 2001; Peter-
son et al. 2011) and without complicating factors such as 
a prior history of psychiatric difficulties (Nevin 2012a; 
Yelmo et  al. 2010) suggest that exposure to prophylactic 
regimens of mefloquine or higher treatment doses are 
associated with side effects, including insomnia (Yelmo 
et al. 2010), depression (Caillon et al. 1992; Javorsky et al. 
2001, Whitworth and Aichhorn 2005), manic behavior 
and/or bipolar disorder (Piening and Young 1996; Yelmo 
et al. 2010), mental confusion and concentration difficul-
ties (Javorsky et  al. 2001; Nevin 2012a; Tor et  al. 2006), 
and memory impairment (Javorsky et  al. 2001; Nevin 
2012a). Especially troubling are reports of symptoms 
indicative of mania and confusional psychoses, includ-
ing symptoms of insomnia, elevated mood and energy, 
disinhibition in social interactions, delusions and hal-
lucinations (Björkman 1989; Javorsky et al. 2001; Kukoyi 
and Carney 2003; Peterson et al. 2011; Piening and Young 
1996; Stuiver et al. 1989; Tor et al. 2006), which have been 
shown to respond to treatment with antipsychotics (Pien-
ing and Young 1996; Tor et al. 2006). Suicide and suicidal 
ideation have been also noted (Jousset et al. 2010). Some 
case studies indicate psychiatric disturbance lasting long 
after treatment was withdrawn (Kukoyi and Carney 2003). 
Larger studies of travelers have also found evidence of 
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depressed feelings, “strange feelings” and other alterations 
in emotional and cognitive functioning (Petersen et  al. 
2000; van Riemsdijk et al. 1997, 2005; Meier et al. 2004), 
especially among women (van Riemsdijk et al. 1997; Phil-
lips and Kass 1996; Schlagenhauf et al. 2009).
The mechanisms by which mefloquine could poten-
tially create adverse effects on mood and emotional func-
tioning are numerous. Mefloquine has also been shown 
to affect gap junction activity by blocking the connexin36 
protein (Nevin 2012c; Voss et  al. 2009; Juszczak and 
Swiergiel 2009; Alisky et al. 2006), to alter dopaminergic 
and cholinergic activity, and calcium homeostasis (Juszc-
zak and Swiergiel 2009; Alisky et  al. 2006; Nevin 2011; 
Allison et  al. 2011), to stimulate 5-HT2A and 5-HT2C 
receptors with similar potency and efficacy as the hal-
lucinogen dimethyltryptamine (Janowsky et al. 2014), to 
alter activity in basolateral amygdala, important to the 
mediation of fear and anxiety states (Chung and Moore 
2009), to impair fear-based learning through blocking 
of hippocampal gap junctions (Bissiere et  al. 2011), to 
potentially alter sleep-waking related activity in reticular 
activating sites (Beck et al. 2008; Garcia-Rill et al. 2007), 
and to antagonize adenosine receptors (Alisky et al. 2006; 
Shepherd 1988). Rodent studies have found that meflo-
quine administration led to changes in sleep phase activ-
ity, motor function (proprioception), lesions in brain 
stem, especially the nucleus gracillis (Dow et  al. 2006), 
and induced tonic seizures (Amabeoku and Farmer 
2005). Thus, mefloquine has the potential to produce 
both acute and long-term deleterious effects.
Given the notable evidence of significant pharmaco-
dynamic and toxicodynamic effects of mefloquine in the 
brain, it is surprising that so few studies have directly 
explored its behavioral effects. Considering the wide vari-
ety of symptoms mefloquine exposure has been linked 
to—elevated energy, insomnia, anxiety, confusion, social 
disinhibition, depression, manic-like and agitated psy-
chotic symptoms, mefloquine may have a fundamental 
disinhibiting effect on emotional regulation—through its 
arousing, fear-related, and even hallucinatory effects and 
effects on neurotransmitters systems related to arousal, 
such as dopamine and adenosine—that could contribute 
to the emergence of a number of psychiatric syndromes. 
To further investigate the etiology of observed behavioral 
effects of mefloquine during clinical use, we explored the 
effects of mefloquine in a rodent model using two murine 
tests of emotional behavior: the light–dark apparatus and 
the tail suspension test. The light–dark apparatus (Bourin 
and Hascoët 2003; Keers et  al. 2012; Flaisher-Grinberg 
and Einat 2010; Shoji et  al. 2012) allows measurement 
of a number of anxiety related variables in mice. Mice 
are placed in an apparatus which gives them a choice of 
exploring a lighted area (which is explored less when the 
subject is anxious) or staying in a more secure, darkened 
compartment. We hypothesize that the acute administra-
tion of mefloquine would lead to a reduction in anxiety-
related behaviors in the apparatus, due to its putative 
effects on emotional regulation.
The tail suspension test is a murine model of depres-
sive-like behavior (Cryan et  al. 2003; Stéru et  al. 1987), 
in which mice are suspended by the tip of their tail for 
a short period of time (Xiaoqing and Gershenfeld 2001). 
This suspension typically leads to initial struggling and 
attempts to escape followed by increasingly lengthy peri-
ods of immobility. Drugs with an antidepressant effect, 
such as desipramine, tend to reduce the amount of time 
spent immobile in this task, as do stimulant drugs such 
as amphetamine and caffeine (Tenn et al. 2005). This test 
has been used to test for manic-like (Shoji et al. 2012; Kir-
shenbaum et al. 2013) as well as depressive-like behavior 
(Wang et al. 2014; Zhu et al. 2014), using time immobile 
as a measure of emotional behavior. We hypothesized 
that acute administration of mefloquine would decrease 
periods of immobility in this test; again, this would be a 
function of mefloquine’s effects on emotional regulation.
Results
Light/dark test
Figure  1a displays the emergence time as a function 
of drug dose (mean  =  23.64, 22.89, 14.68, and 14.3 for 
0, 5, 25, and 100  mg/kg, respectively). Although there 
was a general trend towards shorter emergence laten-
cies, a one-way ANOVA demonstrated no effect of dose, 
F(3,68) = 0.468, p = .693. Figure 1b shows the number of 
rears by dose (mean = 7.77, 13.95, 12.79, and 16.18 for 0, 
5, 25, and 100 mg/kg, respectively). A one-way ANOVA 
showed a significant effect of dose, F(3,68)  =  3.946, 
p  =  .012. Fisher’s LSD showed that 5 and 100  mg/kg 
doses produced a greater number of rears than vehi-
cle, p  <  .05 for both. Figure  1c illustrates the total time 
spent in the light in seconds (mean  =  107.04, 134.35, 
120.78, 156.55, for 0, 5, 25, and 100 mg/kg, respectively). 
A one-way ANOVA revealed a significant effect of dose, 
F(3,68) = 3.359, p = .024, with Fisher’s LSD further show-
ing that the 100 mg/kg dose was significantly greater than 
vehicle, p < .05.
Tail suspension test
Figure  1d–f illustrates the total time spent immobile 
in the tail suspension test by dose. Analysis of Set 1 
(Fig. 1d) showed no significant difference between vehi-
cle and the 5  mg/kg dose (mean  =  196.72 and 211.85, 
respectively), t(23) =  1.165, p =  .256. Analysis of Set 2 
(Fig. 1e) showed no significant difference between vehi-
cle and the 25 mg/kg dose (mean = 185.35 and 175.18, 
respectively), t(26)  =  0.538, p  =  .298. Finally, analysis 
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of Set 3 (Fig. 1f ) showed significantly less immobility in 
the 100  mg/kg group relative to vehicle, t(27) =  3.054, 
p = .005.
Discussion
The results of this study confirmed the hypothesis 
that administration of mefloquine would lead to the 
Fig. 1 Behavior as a function of drug dose. a Emergence latency in the light dark test. b Rearing behavior in the light dark test. c Total time spent in 
the lighted area in the light dark test. d Total immobility time in the tail suspension test for Set 1 (0 vs. 5 mg/kg mefloquine). e Total immobility time 
in the tail suspension test for Set 2 (0 vs. 25 mg/kg mefloquine). f Total immobility time in the tail suspension test for Set 3 (0 vs. 100 mg/kg). All data 
is presented as M ± SEM. *Indicates a significant difference between indicated group and 0 mg/kg controls, p < .05
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emergence of behavior in our subjects indicative of emo-
tional disturbance. Subjects in the light/dark test showed 
an increase in rearing behaviors and time spent in lighted 
areas of the box at the highest dose employed, while 
changes in rearing behavior were noted at the smallest 
dose as well. Emergence latency was highly variable and 
no significant differences were seen, although a general 
trend downwards with increasing doses was suggested. 
Moreover, a decrease in immobility was seen in the tail 
suspension test with the highest dose, further suggesting 
the occurrence of an altered emotional state; lower doses, 
however, had no effect on immobility. This study provides 
converging evidence consistent with case reports of emo-
tionally disinhibited behavior associated with mefloquine 
exposure (Yelmo et al. 2010; Piening and Young 1996).
Greater rearing and time spent in the light in the light/
dark test has traditionally been interpreted as indicating 
lower levels of anxiety (Bourin and Hascoët 2003), and 
decreased immobility in the tail suspension has typi-
cally been interpreted as indicating an anti-depressive 
effect (Wang et al. 2014; Zhu et al. 2014). Our data is not 
incompatible with these possibilities. However, as pre-
viously discussed, mefloquine’s effects on the brain are 
many. Greater activity could be indicative of anxiolysis, 
given mefloquine’s effects in fear-mediating areas of the 
brain (Bissiere et  al. 2011; Chung and Moore 2009), or 
it could be indicative of greater arousal due to effects on 
adenosine (Alisky et al. 2006; Shepherd 1988), serotonin 
(Janowsky et al. 2014), dopamine (Allison et al. 2011), or 
effects on sleep-waking systems (Beck et  al. 2008, Gar-
cia-Rill et al. 2007). The present study on its own, while 
supporting the idea of a fundamental emotional disinhi-
bition, cannot determine whether the behavioral effects 
seen are indicative of anxiolytic, anti-depressive, or 
arousal based effects. Other studies have yielded mixed 
results regarding the question of mefloquine’s effects on 
arousal and activity; for example, Dow et al. (2006) found 
that mefloquine changes some measures of activity in 
rats, such as beam traversal time and time spent active 
during the sleep cycle, but not others, such as in the open 
field test. Future research should address these separate 
possibilities.
The importance of this work is evident when consid-
ering all the complicating factors in determining meflo-
quine’s effects in humans, and especially travelers who 
may be experiencing other events—illness, exhaustion, 
adjustment to a new situation and/or culture—that could 
complicate determinations of causality. Randomized and 
double-blind studies of travelers do exist (Schlagenhauf 
et  al. 2009), but typically rely on participant-provided 
retrospective reporting across a long period of time. The 
features of a controlled study on a homogeneous subject 
population with direct measures of behavior employed 
in an exact time frame, rather than retrospective reports 
gathered after a trip abroad, are especially germane to 
determining the short-term effects of mefloquine. Many 
reports of adverse effects indicate that such effects arose 
shortly after the consumption of the first dose, whereas 
reporting of adverse effects by travelers may take place 
several weeks later.
Of relevance to the current work is the association of 
mefloquine with both depression and mania, both of 
which have been identified in case studies (Yelmo et  al. 
2010; Caillon et al. 1992; Javorsky et al. 2001; Whitworth 
and Aichhorn 2005; Piening and Young 1996). It is pos-
sible that mefloquine’s stimulatory effects—through 
antagonism of adenosine receptors (Alisky et  al. 2006; 
Shepherd 1988) or other mechanisms—could produce 
manic-like behavior within a short time after adminis-
tration. Moreover, due to mefloquine’s long-half life in 
the body, continued stimulation of adenosine receptors 
over the course of many days could continuously inter-
fere with sleep, leading to symptoms of depressed mood 
rather than mania; indeed, insomnia is one of the most 
common adverse effects reported (Yelmo et al. 2010).
Despite these results, interpretation of the current 
study is somewhat complicated by dosing issues. While 
a range of doses was tested, it is unclear which of these 
doses employed best represents a dose given to humans 
for prophylaxis or treatment. In one study of rats, the oral 
doses of mefloquine in corn oil that produce concentra-
tions similar to that seen in humans after prophylaxis and 
treatment are 45 and 187 mg/kg, respectively, 24 h after 
administration (Dow et  al. 2006); however, direct com-
parisons with that study are complicated by differences in 
species and route of administration. As such, this study 
cannot definitively establish that the dose of oral meflo-
quine given to humans for prophylaxis (250 mg weekly) 
or treatment (750 mg or greater) were equivalent to any 
of the doses used in this study with mice. It can be said, 
however, that the emergence of behavioral disturbances 
in our study was noticeable with greater doses, and as 
such, the risk of manic-like behavior is likely greater with 
the larger, treatment dose. This is worth noting in part 
because it would be difficult to determine that meflo-
quine was responsible for behavior disturbances if given 
to a person already assumed to have an active infection 
and likely to suffer post-malaria neurological symptoms 
(Nevin 2012a).
Further complicating understanding of mefloquine’s 
effects on behavior is the fact that mefloquine’s effects 
are idiosyncratic and influenced by the function of the 
P-glycoprotein transmembrane transporter, which medi-
ates mefloquine’s movement across the blood–brain 
barrier (Nevin 2012d). Polymorphisms in the ABCB1/
MDR1 gene coding for P-glycoprotein may account for 
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individual differences in mefloquine accumulation in 
the brain, which in turn have been proposed to mediate 
mefloquine’s treatment efficacy with progressive multi-
focal leukoencephalopathy and might similarly influence 
individual differences in the behavioral effects of meflo-
quine exposure. Considerable differences in behavioral 
sequelae of exposure could result from individual genetic 
differences in influx and efflux of mefloquine from the 
brain.
It should also be noted that other murine tests not 
explored in this study could also be used to establish the 
relationship between acute exposure to mefloquine and 
emotional disinhibition, including the resident-intruder 
test (Einat 2007)—such an approach could also be valu-
able in elucidating mefloquine’s putative relation to 
aggressive behavior—and hedonia as measured by the 
sweetness preference test (Flaisher-Grinberg and Einat 
2009). Studies of startle behavior could be helpful in dis-
ambiguating whether mefloquine’s effects on activity 
in the current study are indicative of anxiolysis or not. 
Should mefloquine have an anxiolytic effect, it should 
decrease startle magnitude; conversely, if mefloquine 
induces a more fundamental emotional disinhibition of 
the kind that that underlies confusional psychosis and 
mania, we should see exactly the opposite. A separate 
issue is whether the effects shown here are the result of 
mefloquine’s effects on adenosine or through some other 
mechanism; studies of co-administration with adeno-
sine antagonists could be illustrative in this regard. In 
the future, we hope to incorporate the use of behavioral 
recording software to more precisely track behavior in 
these and other tests.
Currently mefloquine is considered a fourth-line agent 
for treatment of malaria in many regions (Nevin 2012e), 
in large part because of the risk of adverse effects iden-
tified previously. As such, the reported incidence of 
adverse effects associated with the drug could reasonably 
be expected to diminish over time as providers turn to 
better tolerated, safer alternatives. However, mefloquine 
is still being employed, in part because of established 
resistance to other antimalarials such as chloroquine; 
thus, it seems likely that the issue of potential adverse 
effects will still be relevant in the near future. Moreover, 
there remains the largely unexplored issue of long-term 
adverse effects associated with exposure. It remains to 
be seen how many of those exposed long-term to the 
drug will develop lasting issues, particularly members 
of the military deployed for years overseas. Research on 
longer term effects is especially important given the pos-
sibility of limbic encephalopathy (Nevin 2012a) lesions in 
brainstem and elsewhere (Dow et  al. 2006), and longer-
lasting manifestations of illness mediated by mefloquine 
exposure. Currently our lab is exploring the effects of 
longer-term exposure to the drug. Regardless, the cur-
rent results support the hypothesis that even acute 
mefloquine exposure can induce symptoms of mood 
disturbance.
Conclusions
Our study concludes that acute administration of meflo-
quine leads to some behaviors indicative of emotional 
disinhibition in mice, including increased rearing and 
time in light in the light/dark apparatus and reduced 
immobility in the tail suspension test.
Methods
Subjects
Subjects were 166 male C57BL/6  J mice, approximately 
3–4 months old, bred from stock obtained from Jackson 
Laboratories (Bar Harbor, ME) and housed under stand-
ard conditions with free access to food and water under a 
reverse 12:12 h light:dark cycle with lights off at 10 AM. 
All procedures were approved by the Institutional Ani-
mal Care and Use Committee of Winona State Univer-
sity. Mefloquine hydrochloride (Sigma-Aldrich, St. Louis, 
MO; 5, 25, or 100 mg/kg body weight) in corn oil vehi-
cle or vehicle alone was injected intraperitoneally 24  h 
before testing. Testing was conducted at approximately 4 
PM–6 PM each day.
Light/dark test
The light–dark test was conducted in a darkened room. 
The light–dark apparatus consisted of two chambers 
separated by a black plastic door. The first chamber (start 
box) was a 19 × 14.5 × 20 cm black plastic chamber (dark 
area), with a wooden door that was manually removed at 
the beginning of each test. Outside the doorway, there 
was a chamber measuring 50 × 39 × 20 cm with white-
painted wooden walls and a floor made of white-painted 
wood, above which was a 60-watt bulb that illuminated 
the lighted part of the chamber. At the beginning of test-
ing and in-between sessions, the apparatus was wiped 
clean using a 75.5 % ethanol solution. Subjects were han-
dled daily for several days before the beginning of test-
ing. Subjects were administered 0 (n = 22), 5 (n = 19), 25 
(n = 14) or 100 (n = 17) mg/kg mefloquine 24 h before 
testing. Before testing, subjects were removed from the 
colony room to the darkened testing room for approxi-
mately 10  min. Subjects were then placed in the dark 
box for 30  s. At that point, the doorway between dark 
and lighted areas was opened and the test began. Three 
variables were assessed: (a) the amount of time required 
for each subject to emerge from the dark chamber into 
the lighted field (emergence latency, defined as the time 
after the doorway opened when all four paws entered the 
lighted field), (b) the number of rearing behaviors in the 
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lighted area, and (c) the total time (out of 300 s) spent in 
the lighted field (light time). After a 5-min period, the 
subject was removed from the apparatus and the appa-
ratus was cleaned with ethanol. Sessions were videotaped 
and scored by observers who were blinded to the experi-
mental condition for each subject.
Tail suspension test
The tail suspension apparatus for the acute test consisted 
of a plastic frame supporting a PVC tube (approximately 
2 cm in diameter) approximately 15 cm from the ground. 
Clear tape was used to suspend the subjects from the 
tube by the tip of the tail, ensuring paws remained off 
the ground, even when outstretched. Subjects were han-
dled daily for several days before the beginning of testing. 
Separate groups of subjects were run for each dose com-
parison, such that each group given mefloquine had its 
own separate comparison group. Although this approach 
potentially led to a loss of statistical power, as control sub-
jects from each set could not be combined into a single 
large control group, it was deemed necessary since sepa-
rate sets were scored by different observers. Set 1 subjects 
were given either vehicle (n = 19) or 5 mg/kg mefloquine 
(n = 18); Set 2 subjects, either vehicle (n = 14) or 25 mg/
kg mefloquine (n =  14); Set 3 subjects, vehicle (n =  12) 
or 100  mg/kg mefloquine (n  =  17). Subjects were then 
moved to an illuminated room and affixed to the tube by 
the tip of the tail with clear tape so that they remained 
suspended for 6  min. Sessions were videotaped and 
scored by observers who were blinded to the experimental 
condition for each subject. The variable of interest was the 
amount of time spent immobile (limbs not moving, trunk 
and head immobile) out of 360 s. Mice that climbed their 
tails during the test were eliminated from the project; 5 oil 
treated controls and 7 mefloquine treated mice from the 0 
vs. 5 mg/kg comparison were eliminated for this reason.
Statistics
Data are expressed as mean  +  SEM. All statistics were 
computed using SPSS. Normality of data was confirmed 
using the Shapiro–Wilks test. One-factor ANOVAs and 
Fisher’s LSD post hoc tests were used to compare groups 
for the light–dark test, and independent-samples t test 
(Student’s) were used to compare groups for the tail sus-
pension test, with alpha levels set at .05.
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